Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

cnbc.com/2025/07/16/healthy-returns-chinese-obesity-may-become-a-rival-to-eli-lillys-zepbound-.html

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.

This story appeared on cnbc.com, 2025-07-16 17:19:24.
The Entire Business World on a Single Page. Free to Use →